Cargando…

Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study

BACKGROUND: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatment for inflammatory rheumatic diseases, medication adherence to DMARDs is often suboptimal. Effective interventions to improve adherence to DMARDs are lacking, and new targets are needed to improve adh...

Descripción completa

Detalles Bibliográficos
Autores principales: Voshaar, Marieke, Vriezekolk, Johanna, van Dulmen, Sandra, van den Bemt, Bart, van de Laar, Mart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075197/
https://www.ncbi.nlm.nih.gov/pubmed/27769224
http://dx.doi.org/10.1186/s12891-016-1289-z
_version_ 1782461819291435008
author Voshaar, Marieke
Vriezekolk, Johanna
van Dulmen, Sandra
van den Bemt, Bart
van de Laar, Mart
author_facet Voshaar, Marieke
Vriezekolk, Johanna
van Dulmen, Sandra
van den Bemt, Bart
van de Laar, Mart
author_sort Voshaar, Marieke
collection PubMed
description BACKGROUND: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatment for inflammatory rheumatic diseases, medication adherence to DMARDs is often suboptimal. Effective interventions to improve adherence to DMARDs are lacking, and new targets are needed to improve adherence. The aim of the present study was to explore patients’ barriers and facilitators of optimal DMARD use. These factors might be used as targets for adherence interventions. METHODS: In a mixed method study design, patients (n = 120) with inflammatory arthritis (IA) completed a questionnaire based on an existing adapted Theoretical Domains Framework (TDF) to identify facilitators and barriers of DMARD use. A subgroup of these patients (n = 21) participated in focus groups to provide insights into their facilitators and barriers. The answers to the questionnaires and responses of the focus groups were thematically coded by three researchers independently and subsequently categorized. RESULTS: The barriers and facilitators that were reported by IA patients presented large inter-individual variations. The identified barriers and facilitators could be captured in the following domains based on an adapted TDF: (i) knowledge, (ii) emotions, (iii) attention, memory, and decision processes, (iv) social influences, (v) beliefs about capability, (vi) beliefs about consequences, (vii) motivation and goals, (viii) goal conflict, (ix) environmental context and resources, and (x) skills. CONCLUSIONS: Patients with IA have a variety of barriers and facilitators with regard to their DMARD use. All of these barriers and facilitators could be categorized into adapted domains of the TDF. Interventions that address individual facilitators and barriers, based on capability, opportunity, and motivation, are needed to develop strategies for medication adherence that are tailored to individual patient needs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12891-016-1289-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5075197
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50751972016-10-28 Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study Voshaar, Marieke Vriezekolk, Johanna van Dulmen, Sandra van den Bemt, Bart van de Laar, Mart BMC Musculoskelet Disord Research Article BACKGROUND: Although disease-modifying anti-rheumatic drugs (DMARDs) are the cornerstone of treatment for inflammatory rheumatic diseases, medication adherence to DMARDs is often suboptimal. Effective interventions to improve adherence to DMARDs are lacking, and new targets are needed to improve adherence. The aim of the present study was to explore patients’ barriers and facilitators of optimal DMARD use. These factors might be used as targets for adherence interventions. METHODS: In a mixed method study design, patients (n = 120) with inflammatory arthritis (IA) completed a questionnaire based on an existing adapted Theoretical Domains Framework (TDF) to identify facilitators and barriers of DMARD use. A subgroup of these patients (n = 21) participated in focus groups to provide insights into their facilitators and barriers. The answers to the questionnaires and responses of the focus groups were thematically coded by three researchers independently and subsequently categorized. RESULTS: The barriers and facilitators that were reported by IA patients presented large inter-individual variations. The identified barriers and facilitators could be captured in the following domains based on an adapted TDF: (i) knowledge, (ii) emotions, (iii) attention, memory, and decision processes, (iv) social influences, (v) beliefs about capability, (vi) beliefs about consequences, (vii) motivation and goals, (viii) goal conflict, (ix) environmental context and resources, and (x) skills. CONCLUSIONS: Patients with IA have a variety of barriers and facilitators with regard to their DMARD use. All of these barriers and facilitators could be categorized into adapted domains of the TDF. Interventions that address individual facilitators and barriers, based on capability, opportunity, and motivation, are needed to develop strategies for medication adherence that are tailored to individual patient needs. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12891-016-1289-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-21 /pmc/articles/PMC5075197/ /pubmed/27769224 http://dx.doi.org/10.1186/s12891-016-1289-z Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Voshaar, Marieke
Vriezekolk, Johanna
van Dulmen, Sandra
van den Bemt, Bart
van de Laar, Mart
Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
title Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
title_full Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
title_fullStr Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
title_full_unstemmed Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
title_short Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
title_sort barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075197/
https://www.ncbi.nlm.nih.gov/pubmed/27769224
http://dx.doi.org/10.1186/s12891-016-1289-z
work_keys_str_mv AT voshaarmarieke barriersandfacilitatorstodiseasemodifyingantirheumaticdruguseinpatientswithinflammatoryrheumaticdiseasesaqualitativetheorybasedstudy
AT vriezekolkjohanna barriersandfacilitatorstodiseasemodifyingantirheumaticdruguseinpatientswithinflammatoryrheumaticdiseasesaqualitativetheorybasedstudy
AT vandulmensandra barriersandfacilitatorstodiseasemodifyingantirheumaticdruguseinpatientswithinflammatoryrheumaticdiseasesaqualitativetheorybasedstudy
AT vandenbemtbart barriersandfacilitatorstodiseasemodifyingantirheumaticdruguseinpatientswithinflammatoryrheumaticdiseasesaqualitativetheorybasedstudy
AT vandelaarmart barriersandfacilitatorstodiseasemodifyingantirheumaticdruguseinpatientswithinflammatoryrheumaticdiseasesaqualitativetheorybasedstudy